CrisprBits has developed a platform to build rapid, precise, and affordable POC tests for a wide range of disease and health conditions
The blood test market worldwide is today around $75-80 billion
This drive will expand access to quality diagnostics and help find the ‘missing millions’ – patients that are suffering from TB but not registered in the healthcare system
TIB Molbiol excels in ultra-rapid assay development for emerging infectious diseases, strongly demonstrated during the Covid-19 pandemic
.jpg)
Molbio Diagnostics has been the pioneer in providing access to molecular testing through its Truenat Real Time PCR platform. Sriram Natarajan, Director & CEO, of the company shares his experiences on the journey so far in an interview with Thomas C Thottathil
The deal is expected to close in the fourth quarter of 2021 and will enable Roche to further expand the portfolio. TIB Molbiol excels in ultra-rapid assay development of emerging infectious diseases
Roche and its subsidiary TIB Molbiol have developed three different LightMix Modular Virus kits for the detection of the virus
It is a point-of-care portable, battery-operated, IoT-enabled platform with a sample to result in less than 1 hour
Roche and its subsidiary, Tib Molbiol, confirm that it has tests for research use that identify the SARS-CoV-2 subvariants of concern, Omicron: BA.1, BA.1.1, BA.2, BA.2.2, BA.3 and Delta
Medtech plays a vital role in the healthcare system and players in this field believe that the budget should address some of their concerns if India has to become a formidable player
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)